Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Related Keywords

United States ,America ,Kennethc Anderson , ,Harvard Medical School ,Lebow Institute For Myeloma Therapeutics ,Fda Oncologic Drugs Advisory Committee ,Jerome Lipper Multiple Myeloma Center ,Dana Farber Cancer Institute ,Lebow Institute ,Myeloma Therapeutics ,Kraft Family Professor ,Drugs Advisory Committee ,North America ,Onclive Tv ,Multiple Myeloma ,